larg
group
emerg
virus
known
occasion
transmit
blood
properti
suggest
transmiss
rout
pathogen
includ
sever
acut
respiratori
syndrom
coronaviru
haemorrhag
fever
viru
cchfv
nipah
viru
niv
identifi
world
health
organ
major
infecti
threat
potenti
caus
global
pandem
differ
pathogen
inactiv
techniqu
develop
reduc
elimin
threat
infect
known
emerg
agent
theraflex
macopharma
tourco
franc
novel
method
pathogen
inactiv
treatment
platelet
concentr
pc
pure
physic
system
base
shortwav
uvc
light
penetr
fluid
pc
inactiv
leucocyt
damag
nucleic
acid
theraflex
macopharma
photodynam
pathogen
inactiv
procedur
treatment
plasma
plasma
unit
deriv
singl
blood
donat
illumin
visibl
light
presenc
phenothiazin
dye
methylen
blue
mb
plasma
singlet
oxygen
gener
lead
destruct
viral
nucleic
acid
method
routin
use
europ
year
pathogen
inactiv
system
test
vitro
effect
mani
differ
type
virus
includ
emerg
virus
west
nile
viru
yellow
fever
viru
studi
investig
capac
theraflex
theraflex
system
inactiv
emerg
virus
cchfv
niv
pc
plasma
respect
select
volunt
donor
base
local
standard
practic
regular
blood
donor
fulfil
requir
blood
donat
given
inform
consent
approv
local
ethic
committe
includ
studi
pc
platelet
addit
solut
ssp
macopharma
prepar
pool
five
buffi
coat
previous
describ
store
agit
target
specif
pc
platelet
concentr
approxim
plasma
content
approxim
accord
macopharma
specif
uvc
treatment
pc
air
remov
plasma
unit
pc
pathogen
inactiv
pc
perform
use
theraflex
system
macopharma
accord
manufactur
instruct
describ
previous
pc
irradi
uvc
light
total
dose
joul
per
squar
centimetr
constant
vigor
agit
ensur
uniform
treatment
pathogen
inactiv
plasma
unit
perform
use
theraflex
system
macopharma
describ
previous
plasma
pathogen
inactiv
process
filtrat
leucodeplet
addit
mb
subsequ
illumin
visibl
light
total
dose
accord
instruct
manufactur
system
mb
remov
step
integr
process
step
routin
use
theraflex
system
omit
exclus
analysi
viru
inactiv
effect
illumin
viru
titr
determin
assess
chang
morpholog
cytopath
effect
indic
cell
calcul
accord
method
express
log
tissu
cultur
infecti
dose
log
titrat
perform
initi
sampl
dilut
cytotox
indic
cell
observ
effect
viru
inactiv
calcul
log
reduct
factor
rf
use
formula
rf
r
reduct
factor
spike
total
viru
load
treatment
total
viru
load
treatment
overal
reduct
factor
express
sum
rf
step
limit
detect
lod
assay
defin
lowest
achiev
sampl
concentr
strain
frankfurt
grown
assess
vero
cell
atcc
cchfv
strain
propag
assess
cell
jcrb
niv
strain
malaysia
grown
assay
vero
cell
atcc
prepar
viru
stock
viral
supernat
collect
day
cell
cultur
cell
confluenc
approxim
achiev
centrifug
aliquot
frozen
use
spike
experi
pc
volum
ml
n
per
viru
plasma
unit
volum
ml
n
per
viru
spike
supernat
viru
treat
uvc
mblight
respect
spike
pc
plasma
unit
still
within
specif
respect
pathogen
inactiv
method
light
dose
appli
increment
full
light
dose
treatment
achiev
process
step
sampl
collect
serial
dilut
viru
titrat
order
test
intrins
viru
inactiv
blood
product
refer
sampl
collect
bag
pathogen
inactiv
treatment
store
room
temperatur
test
end
experi
account
intrins
viru
inactiv
blood
product
result
infect
assay
demonstr
uvc
irradi
mblight
inactiv
cchfv
niv
pc
plasma
unit
respect
pc
half
full
uvc
dose
cchfv
infect
level
lod
full
uvc
dose
also
niv
infect
level
lod
tabl
thu
viru
reduct
factor
cchfv
niv
achiev
pathogen
inactiv
system
pc
plasma
alreadi
full
light
dose
cchfv
niv
inactiv
level
lod
tabl
result
correspond
viru
log
reduct
factor
achiev
mblight
treatment
cchfv
niv
respect
plasma
observ
loss
infect
log
lower
spike
case
signific
loss
infect
probabl
caus
innat
immun
factor
neutral
virus
plasma
howev
viru
titr
decreas
control
cours
experi
particular
signific
differ
load
refer
sampl
indic
observ
viru
inactiv
sole
caus
treatment
uvc
mblight
major
argument
use
pathogen
inactiv
technolog
treat
blood
compon
support
proactiv
approach
provid
gener
protect
new
emerg
infecti
agent
continu
challeng
safeti
blood
suppli
convent
reactiv
approach
wait
threat
emerg
agent
identifi
respond
modifi
donor
screen
programm
take
time
ultim
respons
may
quick
enough
prevent
transfus
contamin
blood
product
hundr
known
emerg
human
pathogen
manufactur
pathogen
inactiv
method
requir
continu
test
inactiv
capac
system
new
infecti
agent
studi
inactiv
efficaci
uvc
mblight
first
time
test
cchfv
niv
member
nairovirida
paramyxovirida
famili
also
includ
studi
confirm
efficaci
two
pathogen
inactiv
system
coronavirus
previous
demonstr
result
studi
show
pathogen
inactiv
system
effect
inactiv
three
virus
spike
pc
plasma
sampl
even
light
dose
increment
full
dose
recommend
manufactur
one
limit
studi
number
replic
small
due
safeti
constraint
laboratori
studi
zoonot
virus
must
perform
accord
highest
biosafeti
requir
addit
plate
would
allow
increas
sensit
assay
consequ
improv
log
reduct
valu
could
perform
envelop
rna
coronaviru
emerg
china
spread
addit
countri
thought
anim
viru
spread
human
civet
like
infect
bat
similar
middl
east
respiratori
syndrom
coronaviru
main
rout
transmiss
nosocomi
transmiss
howev
transmiss
famili
member
also
observ
suggest
might
continu
spread
via
transmiss
infect
person
return
affect
area
transmiss
blood
transfus
describ
yet
nevertheless
high
mortal
diseas
yet
fulli
understood
transmiss
mechan
pose
potenti
threat
safeti
blood
suppli
interestingli
detect
viremia
asymptomat
patient
outbreak
suggest
theoret
risk
transmiss
via
blood
product
precautionari
measur
world
health
organ
introduc
recommend
deferr
blood
donat
donor
potenti
expos
australian
red
cross
blood
servic
amend
donor
screen
questionnair
includ
question
identifi
person
symptom
haemorrhag
fever
viru
envelop
rna
viru
nairovirida
famili
cchfv
often
result
mild
febril
ill
may
occasion
caus
sever
haemorrhag
diseas
diseas
first
identifi
crimean
region
former
soviet
union
signific
public
health
concern
cchfv
occur
across
wide
geograph
region
includ
europ
asia
africa
may
expand
new
region
viru
usual
transmit
human
contact
infect
tick
anim
blood
also
transmiss
human
human
via
exposur
infect
blood
bodi
fluid
although
case
cchfv
transmiss
blood
transfus
report
date
incid
cchfv
infect
due
contamin
medic
instrument
document
case
strongli
reminisc
transmiss
rout
mani
virus
niv
envelop
viru
belong
paramyxovirida
famili
report
first
time
malaysian
popul
reappear
differ
occas
asia
niv
diseas
spectrum
rang
asymptomat
infect
acut
respiratori
ill
fatal
enceph
niv
zoonot
viru
transmit
human
anim
bat
pig
also
transmit
contamin
food
directli
close
contact
bodi
fluid
excret
avail
data
particularli
find
viral
load
differ
bodi
fluid
limit
provid
full
understand
transmiss
rout
transfus
implic
potenti
transmiss
pathway
date
incub
period
day
occurr
latent
infect
subsequ
reactiv
niv
month
even
year
exposur
suggest
infect
person
may
overlook
donor
screen
programm
howev
potenti
transfus
risk
may
limit
fact
asymptomat
mild
niv
infect
rare
futur
studi
need
determin
whether
cchfv
andor
niv
transmit
transfus
one
virus
transfus
transmiss
threshold
concentr
elicit
diseas
must
examin
determin
whether
capac
pathogen
inactiv
technolog
inactiv
respect
viru
plasma
pc
suffici
prevent
transfus
transmiss
interpret
pathogen
load
relationship
infect
inactiv
efficaci
gener
complex
task
attempt
import
consid
quantit
polymeras
chain
reaction
qpcr
commonli
use
approach
measur
viral
load
detect
small
fragment
viral
genom
result
may
reflect
infect
qpcr
usual
overestim
titr
circul
infecti
agent
contrast
infect
assay
use
previou
studi
determin
inactiv
capac
pathogen
inactiv
method
base
intact
function
viral
unit
nevertheless
log
reduct
factor
observ
studi
safeti
margin
calcul
inactiv
level
achiev
use
fraction
standard
light
dose
suggest
theraflex
theraflex
pathogen
inactiv
technolog
may
effect
reduc
potenti
risk
cchfv
niv
relat
virus
platelet
plasma
transfus
ft
sr
employe
macopharma
manufactur
distributor
theraflex
pathogen
inactiv
pi
system
ug
wh
thm
receiv
project
grant
german
red
cross
blood
servic
macopharma
develop
pi
technolog
platelet
conflict
interest
disclos
eickmann
design
studi
interpret
data
manuscript
u
gravemann
design
studi
perform
vitro
experi
analys
data
w
handk
perform
vitro
experi
analys
data
f
tolksdorf
interpret
data
edit
manuscript
reichenberg
interpret
data
edit
manuscript
h
interpret
data
edit
manuscript
seltsam
design
studi
interpret
data
wrote
manuscript
author
read
approv
final
manuscript
work
support
german
red
cross
blood
servic
deutsch
forschungsgemeinschaft
der
blutspendedienst
de
deutschen
roten
kreuz
macopharma
sa
